CD274 and neoplasm: Nonetheless, since PD-L1 expression is very heterogeneous in the tumor, it is difficult to accurately define the true PD-L1 status in the whole tumor using a single core biopsy [27,28,29], thus potentially explaining why only a fraction of patients treated with immunotherapy, between 20–40%, shows a stable and lasting response [30].